# Fgfr4 combined with inflammatory cytokines improves recurrence risk prediction in differentiated thyroid carcinoma: A retrospective cohort study

**Authors:** Yongjie Hu, Peifei Huang, Yingying Sha

PMC · DOI: 10.5937/jomb0-59084 · Journal of Medical Biochemistry · 2026-01-06

## TL;DR

This study shows that combining FGFR4 and inflammatory cytokines improves the prediction of thyroid cancer recurrence after surgery.

## Contribution

A new combined predictive model using FGFR4 and inflammatory cytokines for DTC recurrence risk is proposed.

## Key findings

- Preoperative FGFR4 and inflammatory cytokine levels were significantly higher in DTC patients.
- The combined model outperformed individual biomarkers in predicting recurrence (AUC=0.864).

## Abstract

This study aimed to evaluate the synergistic role of fibroblast growth factor receptor 4 (FGFR4) and inflammatory cytokines (ICs) (interleukin-6 [IL-6], tumor necrosis factor-a [TNF-a], and C-reactive protein [CRP]) in predicting recurrence of differentiated thyroid carcinoma (DTC) after radical surgery, and to develop a combined predictive model for improved postoperative risk stratification.

We enrolled 102 DTC patients treated between February 2022 and January 2024, along with 98 healthy controls. Serum levels of FGFR4, IL-6, TNF-a, and CRP were measured preoperatively and postoperatively using ELISA. Independent risk factors were identified through logistic regression, diagnostic performance was assessed using ROC analysis, and correlations of FGFR4 and ICs with postoperative recurrence were evaluated.

Preoperative levels of FGFR4, IL-6, TNF-a, and CRP were significantly elevated in DTC patients compared to healthy controls (P&lt;0.05). A diagnostic model integrating these four markers demonstrated superior performance (AUC=0.931; sensitivity 94.12%, specificity 79.59%) over individual biomarkers (P&lt;0.05). Among DTC patients, those with recurrence (n = 26) exhibited significantly higher FGFR4 and inflammatory cytokine levels than the non-recurrent group (P&lt;0.05). The combined model predicted 1-year recurrence with an AUC of 0.864 (sensitivity 73.08%, specificity 93.42%).

The synergistic interaction between FGFR4 and ICs plays a critical role in DTC. Their combined detection enhances postoperative recurrence risk prediction, offering a valuable tool for clinical risk stratification.

## Linked entities

- **Genes:** FGFR4 (fibroblast growth factor receptor 4) [NCBI Gene 2264]
- **Proteins:** IL6 (interleukin 6)
- **Diseases:** differentiated thyroid carcinoma (MONDO:0015447)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, FGFR4 (fibroblast growth factor receptor 4) [NCBI Gene 2264] {aka CD334, JTK2, TKF}, TG (thyroglobulin) [NCBI Gene 7038] {aka AITD3, TGN}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** breast cancer (MESH:D001943), metastasis (MESH:D009362), DTC (MESH:D013964), infections (MESH:D007239), autoimmune disorders (MESH:D001327), PTC (MESH:D000077273), inflammatory (MESH:D007249), hereditary thyroid cancer syndromes (MESH:D009386), cancer (MESH:D009369)
- **Chemicals:** glutamine (MESH:D005973), H2SO4 (MESH:C033158), radioactive iodine (-), 3,3',5,5'-tetramethylbenzidine (MESH:C021758)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967172/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967172/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967172/full.md

---
Source: https://tomesphere.com/paper/PMC12967172